<DOC>
	<DOC>NCT01151904</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.</brief_summary>
	<brief_title>Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Angle-Closure</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patient has been administering latanoprost eye drops in affected eye(s) for at least 12 weeks prior to study Patient must have at least partially responded to latanoprost and requiring further IOP lowering eye drops Diagnosis of chronic angleclosure glaucoma Patients using COMBIGAN® in the past must not have been discontinued due to adverse events or lack of efficacy. Known allergy or hypersensitivity to COMBIGAN® Corneal abnormalities that would preclude accurate IOP readings Any other active ocular disease other than glaucoma or ocular hypertension Ocular surgery within the past 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>